|Year : 2021 | Volume
| Issue : 1 | Page : 16-23
The Role of Echocardiography in Heart Failure Today
Jostol Pinto1, A George Koshy2
1 Department of Cardiology, Father Muller Medical College, Mangalore, Karnataka, India
2 Department of Cardiology, Government Medical College, Trivandrum, Kerala, India
|Date of Submission||05-May-2020|
|Date of Decision||13-Aug-2020|
|Date of Acceptance||23-Oct-2020|
|Date of Web Publication||27-Feb-2021|
Prof. A George Koshy
Department of Cardiology, Government Medical College, Trivandrum, Kerala
Source of Support: None, Conflict of Interest: None
Although heart failure (HF) is often defined clinically, it has a large pre-clinical spectrum and its diagnosis, staging, response to therapy, and etiology are often determined by echocardiography. Understanding of pathophysiologic nuances in HF is significantly aided by the novel parameters that modern echocardiography can assess today, especially in the field of diastolic function and imaging of strain. This article attempts to link the understanding of the progression of HF with an applicable echocardiographic approach to patients at any point in this progression, sometimes in special clinical scenarios. It also conveys that how systolic and diastolic dysfunction is not mutually exclusive but can be assessed separately or simultaneously. Early HF can be subclassified based on myocardial deformation being dysfunctional either longitudinally or circumferentially. An insight into right ventricular evaluation is also included here.
Keywords: Echocardiography, heart failure, systolic and diastolic dysfunction, strain imaging
|How to cite this article:|
Pinto J, Koshy A G. The Role of Echocardiography in Heart Failure Today. J Indian Acad Echocardiogr Cardiovasc Imaging 2021;5:16-23
|How to cite this URL:|
Pinto J, Koshy A G. The Role of Echocardiography in Heart Failure Today. J Indian Acad Echocardiogr Cardiovasc Imaging [serial online] 2021 [cited 2021 Jul 23];5:16-23. Available from: https://www.jiaecho.org/text.asp?2021/5/1/16/310493
| Understanding Definitions|| |
The American College of Cardiology/American Heart Association (ACC/AHA) guideline defines heart failure (HF) as “a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood.” The HF Association of the European Society of Cardiology (ESC) more elaborately defines HF as “a clinical syndrome characterized by typical symptoms (breathlessness, ankle swelling, and fatigue) that may be accompanied by the signs (elevated jugular venous pressure, pulmonary crackles, and peripheral edema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.” Although this definition omits patients in ACC/AHA stages A and B (described later), the ESC itself recommends that starting treatment at the precursor stages A and B may reduce mortality., Irrespective of the stage or symptom status, objective demonstration of a cardiac cause is central to the diagnosis of HF.
In simpler terms, HF is the inability of the heart to deliver a satisfactory output at normal filling pressures.
| Impact of Heart Failure|| |
Globally, HF affects over 40 million people, 2% of all adults and over 10% of those above 70 years of age.,, A conservatively estimated prevalence of HF in India about 10 years ago was around 1.3-4.6 million with an annual rise of 0.4-1.8 million. A more recent community-based survey of 10,163 adults in rural India in 2016 showed a prevalence of 1.2 per 1000 with a mean age of 58.3 ± 10.4 years.
Compared to the Western population, Indians with HF have a higher rate of hospital mortality, 1-year mortality, and younger age of onset with a greater male preponderance of 70:30.
| The Spectrum of Heart Failure and the Role of Echocardiography|| |
HF involves the loss of functioning myocytes after an abrupt or insidious inciting event resulting in progressive dilation or hypertrophy of the left ventricle (LV), followed by spherical remodeling.
According to the 2013 ACC/AHA guideline for the management of HF, it may be classified into four stages:,
- Stage A: At high risk for developing HF, but no functional or structural disorder. These include patients with hypertension, coronary artery disease (CAD), diabetes mellitus, or with family history of cardiomyopathy
- Stage B: With a structural heart disorder but without signs or symptoms. This comprises people who have suffered an acute coronary syndrome in the past, who have asymptomatic LV systolic dysfunction or who have asymptomatic valvular heart disease
- Stage C: Previous or current symptoms of HF (shortness of breath, fatigue, and reduced exercise tolerance) with structural heart disease
- Stage D: Advanced disease requiring hospital-based support, heart transplant, or hospice.
The number of patients with LV systolic dysfunction in stage B is four times that of stages C and D put together. A population-based study of a random sample of 2029 residents aged over 45 years revealed that while only 32% of people had “no HF,” 22% were in stage A (at risk), 34% were in stage B (asymptomatic), 12% were in stage C (symptomatic), and 0.2% in stage D (refractory). Survival at 5 years was 99%, 97%, and 96% for those who had no HF, those in stage A and those in stage B, respectively. Those in stage C and D, however, had a 5-year survival of only 75% and 20%, respectively.
This classification of HF by the ACCF/AHA when applied on the Olmsted County resident cohort showed that 56% of adults had asymptomatic stage A or B HF (a large subclinical spectrum) while 12% had symptomatic HF.,,
Only echocardiography can truly categorize individuals into “no HF,” preclinical stage A or stage B. Stage B HF may be an incidental finding on echocardiography in the absence of not only history, symptoms and clinical signs, but also without any risk factors for HF (no prior stage A). In stages C and D, echocardiography serves as a prognostic tool to stage the severity and progression of HF.
Today, echocardiography has unmatched utility and safety in diagnosing and prognosticating systolic and/or diastolic dysfunction and suggesting an etiology. It is also essential to objectively explain a patient's symptoms as over 30% of patients with a clinical suspicion of HF may not actually have HF.
Echocardiographically, HF is often classified based on LV ejection fraction (LVEF) as that with reduced (HFrEF, LVEF ≤40%), mid-range (HFmrEF, LVEF 41%–49%) or preserved (HFpEF, LVEF ≥50%) ejection fraction (EF). This classification has replaced the earlier one dividing HF into systolic and diastolic HF. The predicted survival for HFpEF after hospitalization for HF is 35%–40% at 5 years. However, HFpEF seems to be more sinister as it shows a greater prevalence of hypertension and atrial fibrillation,, noncardiac deaths, and refractoriness to therapy when compared to HFrEF.
| Echocardiographic Approach in Heart Failure|| |
A basic echocardiographic evaluation of a patient with known or suspected HF should include M-mode, two-dimensional (2D) echocardiography, color Doppler, pulse-wave Doppler, and continuous-wave Doppler; evaluation of strain provides better insights. Assessing LV diastolic function, right ventricular (RV) function and estimating right atrial (RA) pressures are as important as assessment of systolic function while evaluating for HF. Detection of co-existent valvular disease, possible intracardiac thrombi, or dilated cardiac chambers guide the need for valve interventions, anticoagulation, or treatment of arrhythmias.
Tissue doppler imaging (TDI) and speckle-tracking echocardiography (STE) have increased our understanding of LV myocardial mechanics. While TDI helps us better evaluate diastolic function and myocardial performance index (MPI), STE-based strain helps us detect subclinical LV or RV systolic dysfunction. Real-time three-dimensional (3D) echo is superior to 2D echo as it minimizes the errors of formulae and fore-shortening. Contrast echocardiography helps delineate endocardial borders better, and although less frequently employed, it does help in better visualization of thrombus, aneurysm, noncompaction, and apical hypertrophic cardiomyopathy. Stress echocardiography is used predominantly in the evaluation of CAD but also has a role in HF to look for systolic reserve and early diastolic dysfunction.
Transthoracic echocardiography is recommended in HF in only select clinical scenarios:
- Initial evaluation of suspected systolic or diastolic dysfunction
- Re-evaluation in case of change in clinical status without change in medication or diet
- Cardiac resynchronization therapy (CRT) device optimization
- HF suspected due to suboptimal pacing device settings
- Potentially cardiotoxic chemotherapy.
Routine surveillance of HF without change in clinical status is not recommended.
Transesophageal echocardiography is not routinely done in HF unless the patient has a co-existent cardiac condition such as valvular heart disease, prosthetic valve, or congenital heart disease.
The utility of stress echocardiography has been extended into the domains of systolic and diastolic HF, nonischemic cardiomyopathy, and athlete's hearts. Normally, global contractile reserve is said to be adequate if there is an increase in LVEF by >5% and flow reserve is adequate when there is an increase in forward stroke volume by >20%.
As a general rule, linear internal measurements should be obtained from 2D images to avoid oblique sections. The Teichholz and Quinones methods are no longer recommended. LV volumes and EF should be measured using 3D imaging or modified Simpson's biplane method. The end-diastole is measured at the first frame after mitral valve closure and end-systole is measured at the first frame after aortic valve closure. Left atrial (LA) volume should be preferably measured by the biplane-area-length method.
The evaluation of the LV function and geometry in patients with HF uses various echocardiographic parameters which may be outlined, as shown in [Table 1]:
While assessing LV systolic function, normal LVEF by biplane method ranges between 53% and 73% for the Indian adult., Further LV sphericity index (LV length/diameter in apical four-chamber view) of < 1.5 is abnormal. HFrEF involves the slippage of cardiomyocytes, eccentric LV remodelling (increased LV cavity size without increase in LV mass or wall thickness) or LV wall thinning and increased sphericity.
In contrast, HFpEF is associated with these morphologic adaptations of the left ventricle:
- Normal LV geometry (seen in 30% of patients with HFpEF)
- Concentric left ventricular hypertrophy (LVH) (35%): Increased LV mass with proportionally increased LV wall thickness
- Concentric remodeling (30%): Increased wall thickness but no significant increase in LV mass
- Eccentric LVH (8%): Increased LV mass without proportionately increased wall thickness.
Focused approach to left ventricular systolic dysfunction and heart failure with reduced ejection fraction
Systolic dysfunction may be estimated directly or indirectly based on linear measurements, 2D measurements, spectral Doppler, and 3D evaluation.
Methods of the past which are not recommended today include mitral annular plane systolic excursion, fractional area change and Teichholz method, although the latter is still employed at various centers. The magnitude of mitral valve opening called E-point septal separation (EPSS) is an indirect M-mode marker of LV systolic function. It is actually the minimum distance between the tip of the anterior mitral leaflet and the interventricular septum measured during diastole in the parasternal long-axis view. Normally, EPSS should be <6 mm; this value increases as EF falls. Similarly, aortic valve opening in M-mode is more “rounded” as it closes when forward flow reduces.
A more reliable 2D method to calculate EF is the Simpson biplane method or the rule of disks. Here, the endocardial border of the LV is traced (excluding papillary muscles and trabeculae from the cavity) in the four-chamber and two-chamber views in the systole and diastole, and the volume of the ventricle is calculated. A proper apical view requires the transducer to be at the true apex, the beam passing through the center of the LV and obtaining the greatest apex-to-base dimension. Accurate endocardial border definition may sometimes necessitate the usage of intravenous contrast. Other indirect evidences of systolic dysfunction may be observed as LV dilation, regional wall motion abnormality or absence of systolic wall thickening; however, they do not necessarily reflect the magnitude of global systolic function.
In the presence of mitral regurgitation, using spectral Doppler at a high sweep speed of 100 mm/s, LV dP/dt may be calculated from the points in time (in ms) where mitral regurgitation jet velocity changes from 1 m/s to 3 m/s (corresponding to a pressure change of 36 − 4 = 32 mmHg) and a dP/dt of <1200 mmHg/s suggests LV systolic dysfunction. As this gradient is from the LV to LA, it is a relatively load-independent measure of LV contractility.
A more accurate assessment of LV volume is obtained by advanced 3D echocardiography which is independent of the imaging plane and free from LV cavity geometric assumptions. This thus has high inter- and intra-observer reproducibility. Additional algorithms or software modules need to be in place to assess the same for the RV.
The role of deformation, strain, and torsional evaluation in the evaluation of systolic dysfunction has been discussed in a later section.
Focused approach to left ventricular diastolic dysfunction and heart failure with preserved ejection fraction
LV diastolic filling pressures may refer to any of the following:
- Pulmonary capillary wedge pressure (PCWP)
- Mean left atrial pressure (mLAP)
- LV pre-A pressure
- Mean LV diastolic pressure
- LV end-diastolic pressure (LVEDP)
In early stages of LV diastolic dysfunction, LVEDP alone rises (mitral A velocity, deceleration time (DT) of mitral A, Ar-A >30 ms, mitral a') due to a large atrial pressure wave, while PCWP and mLAP remain normal. With tachycardia or increased LV afterload, we observe rise in PCWP and mLAP (mitral E/A, E-velocity, DT of mitral E, E/e', tricuspid regurgitation (TR) velocity, and pulmonary S/D), which support the rationale of diastolic stress echocardiography.
The four recommended variables that suggest LV diastolic dysfunction are as follows:
- Average E/e' ratio >14 (most accurate)
- Annular e' velocity (septal e' <7 cm/s, lateral e' <10 cm/s)
- LA volume index >34 mL/m2
- Peak TR velocity >2.8 m/s.
Using cutoffs as septal E/e' >15 or lateral E/e' >13 are also acceptable parameters, but the average E/e' is preferred. The recommended approach by the American Society of Echocardiography and the European Association of Cardiovascular Imaging is outlined in [Figure 1].
|Figure 1: Algorithm to grade left ventricle diastolic dysfunction. CAD = Coronary artery disease, LAP = Left atrial pressure, S/D = systolic/diastolic, TR = Tricuspid regurgitation. (From: Nagueh SF, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314)|
Click here to view
E/A >2 may also be seen in athletes and individuals under 40 years of age (due to supranormal suction force generated during early diastole), and immediately after direct current cardioversion (diminutive A wave due to atrial stunning).
Grade III LV diastolic dysfunction is often also reflected in mitral E DT <160 ms, isovolumic relaxation time (IVRT) <50 ms, and septal and lateral e' velocities <4 cm/s, but these do not form the part of routine assessment.
For an overall assessment of diastolic dysfunction, the following cutoffs may be kept in mind [Table 2], although no single parameter should be considered in isolation:,
Occasionally, a mitral “L wave” may be seen in LV diastolic dysfunction but may also be seen rarely in normal individuals with bradycardia. It represents ongoing LV filling in mid diastole.
Septal E/e' >15 generally reflects PCWP >20 mmHg, and if the ratio is <8, it usually means that the PCWP is normal. For intermediate values, other parameters may be evaluated. Similarly, Ar-A >30 ms also suggests an elevated LVEDP of >18 mmHg.
Aging can confound with the evaluation of diastolic dysfunction causing reduced mitral E/A, mitral E DT, and annular e' velocity. However, there are indices which more definitively indicate diastolic dysfunction in the elderly: E/e' >14, mitral inflow changes with Valsalva maneuver, Ar-A >30 ms, elevated resting pulmonary artery systolic pressure (PASP), LA dilation, or LV hypertrophy.
Focused approach to heart failure in special scenarios
In special clinical scenarios, assessment of elevated LV filling pressures (LV diastolic dysfunction) needs additional focus on certain echocardiographic pointers, as listed in [Table 3]:
|Table 3: Assessing left ventricular diastolic function in special clinical scenarios - specific echocardiographic parameters|
Click here to view
Novel parameters being studied include LV untwisting rate, arterial tree pathologic wave reflection, and late systolic wall stress.
LA structure and function are meaningful markers of LV filling pressure (in the absence of mitral valve abnormalities). HFpEF makes the less compliant LV overtly dependent on the atrial pump function. LA dilation is found in about half of all patients with HFpEF, while atrial fibrillation is seen in nearly 40% of HFpEF. Of late, “LA peak reservoir strain” has emerged as a newer parameter showing promise in recognizing earlier stages of HFpEF.
Subclinical diastolic dysfunction or unexplained dyspnea is often encountered in our clinical practice and patients may have intermediate E/e' values between 8 and 15. This subset may benefit from diastolic stress echocardiography., Parameters are recorded at baseline, at low-level exercise, and during recovery: Mitral E, Mitral A, annular e', and PASP. Absence of new regional wall motion abmormality, LV outflow tract obstruction, dynamic mitral regurgitation, and chronotropic incompetence favors a diagnosis of HFpEF, so does an increase in the PASP to >43 mmHg or E/e' >14, peak TR velocity >2.8 m/s. Trained athletes can generate peak TR velocity >3.1 m/s after exercise. Patients with E/e' <15 at rest but >15 with leg raise are said to have unstable relaxation abnormality.
Cohesive evaluation of systolic and diastolic dysfunction
The global assessment of both systolic and diastolic function may be assessed by the Tei index or myocardial performance index (MPI) which is calculated as the ratio between the durations of (isovolumic relaxation + isovolumic contraction)/(ejection time). In short, MPI = (IVRT + IVCT)/ET. The Tei index is independent of heart rate and blood pressure and is easily reproducible even in patients with poor echo windows. Further, it may be applied to the LV and the RV. Normal values of Tei index are <0.4 for LV and <0.3 for the RV.
Rationale of myocardial deformation imaging in heart failure
While the RV generates most of its ejection by longitudinal deformation, the LV is characterized by longitudinal and circumferential shortening and radial thickening, as well as shearing in the circumferential-radial, longitudinal-radial, and circumferential-longitudinal planes. The circumferential-longitudinal shear deformation is called LV twist, which becomes possible due to the double-helical orientation of LV myocardial architecture, where endocardial fibers predominantly align alone the long axis of the LV and epicardial fibers are predominantly circumferentially aligned, subtending an angle of about 60° between each other. The earlier subendocardial and later subepicardial activation during systole results in rotation of the LV base (clockwise) and apex (counter-clockwise) in opposite directions, a mere 20% shortening of myocytes translates into >55% reduction in LV cavity volume. This is the basis of assessing myocardial deformation to detect milder and even subclinical forms of systolic HF.
Healthy adults are expected to have a peak LV global longitudinal strain (GLS) of around -20%, which normally decreases (numerically) with age.
Impaired contraction of one layer (say, subendocardial) may be compensated by another layer thereby maintaining an apparent “normal LVEF” during early stages of HF. Subendocardial fibers are more susceptible to injury/ischemia, and hence, their impairment leads to reduced longitudinal function and right-handed helix shortening with unbalanced subepicardial left-handed helix shortening and increased circumferential shortening. Reduced longitudinal strain (with exaggerated or normal circumferential function) with preserved LVEF is often seen in patients with increasing age, hypertension, diabetes mellitus, and obesity who have HFpEF.
Hence, HFpEF is not necessarily caused by diastolic dysfunction alone; systolic function can still be abnormal albeit with normal LVEF. GLS quantifies the longitudinal shortening during systole and this has been shown to be impaired in HFpEF.,,, In later stages, once the circumferential shortening also gets impaired, measured as reduced global circumferential strain (GCS), it finally leads to HFrEF.
Probably, the earliest echocardiographic indices to detect HFpEF would be impaired longitudinal strain, LV twist and untwist unmasked by exercise.
The LV twist also links systole with diastole. Systolic deformation stores the mechanical energy which facilitates rapid untwisting, recoil, and thus suction during diastole. Parameters to be assessed include: displacement, velocity, strain, strain rate, LV torsion, torsional rate, early diastolic untwist, and percentage of untwist.
Based on the myocardial deformation abnormalities, early HF can be subclassified into three categories as follows:
- HF with predominant longitudinal dysfunction: (seen in severe aortic stenosis) Subendocardial impairment with compensatory hypertrophy and unopposed contractility of subepicardial layers maintains a normally preserved EF. LV circumferential strain and twist may be increased. As early relaxation is the most energy-demanding phase of the cardiac cycle, this subendocardial dysfunction leads to progressive diastolic dysfunction which is worsened with the onset of myocardial fibrosis leading to HFpEF
- HF with predominant circumferential dysfunction: (seen in myopericardial diseases) the subendocardial layer may compensate for the reduced subepicardial contraction, thus maintaining normal LVEF. The loss of LV twist, however, results in reduced LV suction and thus LV diastolic dysfunction sets in
- HF with transmural (longitudinal, radial, and circumferential) dysfunction: (seen in acute myocardial infarction and myocarditis) characterized by reduced LVEF and progressive LV dilation, often presenting as HFrEF.
In the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, among HFpEF patients, reduced GLS was the most important echocardiographic predictor of cardiovascular death or worsening HF. In the Valsartan in Acute Myocardial Infarction (VALIANT) trial, both GLS and GCS were independently associated with all-cause mortality and combined HF death or hospitalization. Increased LV segmental time-to-peak velocity and strain rate also had increased risk of all-cause mortality and HF hospitalization. Apart from this, strain imaging has many other applications in HF. STE-based radial strain can guide the identification of the optimal site for LV lead placement during CRT. Improved GLS after CRT has shown to predict responders and lesser all-cause mortality at 1-year follow-up.
| Right Heart Evaluation in Heart Failure|| |
Pulmonary hypertension and RV dysfunction are highly prevalent in HFpEF. RV assessment includes measuring RA volume, RV size, systolic function, and RV systolic pressure and involves parameters, as listed in [Table 4].,
While assessing RA pressure using the inferior vena cava (IVC), it should be remembered that the IVC is often dilated in young athletes and in patients on positive-pressure ventilation.
Echocardiography may be used to estimate RA pressure using the IVC, RV systolic pressure using the TR jet (thus pulmonary arterial systolic pressure), pulmonary arterial diastolic pressure (equivalent to PCWP estimated by LV E/e'), and mean pulmonary pressure using the pulmonary regurgitation jet. Hence, the group of echo parameters comprised by assessment of IVC, TR jet, pulmonary regurgitation jet, and E/e' is sometimes called “Echo Right Heart Catheterization.”
| Conclusion|| |
Echocardiography is indeed the single most useful tool to diagnose and evaluate HF in all its forms and stages. It stages and sub-types HF, reveals its etiology and complications, and guides medical and device-based therapy. The role of echocardiography has commendable potential to delve even further into the depths of our understanding of HF and clarifying nuances in this field.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al
. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-e327.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al
. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC); Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J 2016;37:2129-200.
Wang TJ. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108:977-82.
Cheesman MG, Leech G, Chambers J, Monaghan MJ, Nihoyannopoulos P. Central role of echocardiography in the diagnosis and assessment of heart failure. Heart 1998;80:S1-5.
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545-1602.
Metra M, Teerlink JR. Heart failure. Lancet 2017;390:1981-95.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93:1137-46.
Huffman MD, Prabhakaran D. Heart failure: Epidemiology and prevention in India. Natl Med J India. 2010; 23:283-8.
Chaturvedi V, Parakh N, Seth S, Bhargava B, Ramakrishnan S, Roy A, et al
. Heart Failure in India: The INDUS (INDia Ukieri Study) study. J Pract Cardiovasc Sci 2016; 2:28-35. [Full text]
Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, et al
. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail 2015;17:794-800.
Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in Heart Failure. J Am Coll Cardiol 2007; 50:381-96.
Mann DL. Management of Patients with Heart Failure with Reduced Ejection Fraction. In: Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's Heart Disease. 10th ed. Philadelphia: Saunders Elsevier; 2015. p. 517.
Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006;113:2851-60.
Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett Jr JC, et al
. Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community. Circulation 2007; 115:1563-70.
Oh JK: Echocardiography in heart failure: beyond diagnosis. Eur J Echocardiogr 2007;8:4-14.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-9.
Gupta DK, Solomon SD. Imaging in HF with preserved ejection fraction. Heart Fail Clin. 2014; 10: 419-34.
Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014; 35:1022-32.
Berry C, Doughty RN, Granger C, Køber L, Massie B, McAlister F, et al
. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with HF with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J. 2012; 33:1750-7.
Guha S, Harikrishnan S, Ray S, Sethi R, Ramakrishnan S, Banerjee S, et al
. CSI position statement on management of heart failure in India. India Heart J 2018:S1-72.
Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, et al
. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/ SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J Am Soc Echocardiogr 2011;24:229-67.
Picano E, Pellikka PA. Stress echo applications beyond coronary artery disease. Eur Heart J 2014; 35:1033-40.
Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al
. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2017;30:101-38.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al
. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.
Omar AMS, Bansal M, Sengupta PP. Advances in Echocardiographic Imaging in Heart Failure with Reduced and Preserved Ejection Fraction. Circ Res 2016; 119:357-74.
Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. Population-based reference values for 3D echocardiographic LV volumes and ejection fraction. JACC Cardiovasc Imaging 2012;5:1191-7.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al
. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314.
Armstrong WF, Ryan T. Evaluation of left ventricular diastolic dysfunction. In: Armstrong WF, Ryan T. Feigenbaum's Echocardiography. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 175-9.
Ommen S, Nishimura R, Appleton C, Miller FA, Oh JK, Redfield MM, et al
. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures. Circulation 2000;102:1788-94.
Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in Heart Failure. J Am Coll Cardiol 2007;50:381-96.
Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, et al
. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014;7:104-15.
Linssen GCM, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL, et al
. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2011;13:1111-20.
Singh A, Addetia K, Maffessanti F, Mor-Avi V, Lang RM. LA strain categorization of LV diastolic dysfunction. JACC Cardiovasc Imaging 2017;10:735-43.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al
. Task Force for the Diagnosis and Treatment of Acute and Chronic HF 2012 of the European Society of Cardiology. Eur J Heart Fail 2012;14:803-69.
Oh JK, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. Circ Cardiovasc Imaging 2011;4:444-55.
Modin D, Andersen DM, Biering-Sorenson T. Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides? Echo Res Pract 2018;5:R65-79.
Kuznetsova T, Herbots L, Richart T, D'hooge J, Thijs L, Fagard RH, et al
. Left ventricular strain and strain rate in a general population. Eur Heart J 2008; 29:2014-23.
Narayanan A, Aurigemma GP, Chinali M, Hill JC, Meyer TE, Tighe DA. Cardiac mechanics in mild hypertensive heart disease: a speckle-strain imaging study. Circ Cardiovasc Imag 2009; 2:382-90.
Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110: 3081-7.
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al
. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015;132:402-14.
Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, et al
. VALIANT investigators. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 2010; 56:1812-22.
Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, et al
. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. Circulation. 2010;121:1096-103.
Park JH, Negishi K, Grimm RA, Popovic Z, Stanton T, Wilkoff BL, et al
. Echocardiographic predictors of reverse remodelling after cardiac resynchronization therapy and subsequent events. Circ Cardiovasc Imaging 2013;6:864-72
Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfeld MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 2009;53:1119-26.
Guha S, Harikrishnan S, Ray S, Sethi R, Ramakrishnan S, Banerjee S, et al
. CSI position statement on management of heart failure in India. India Heart J 2018:S1-7.
[Table 1], [Table 2], [Table 3], [Table 4]